Choose DARZALEX FASPRO® to treat newly diagnosed patients with multiple myeloma, regardless of transplant status

For advanced practice providers (APPs) and nurses

Resources for your practice to help your patients

Tap into education and guidance to support you and your patients along their treatment journey

DARZALEX FASPRO® MOA video

Explains the science behind daratumumab and hyaluronidase, the active ingredients in DARZALEX FASPRO®

DARZALEX® MOA video

Explains how daratumumab, the active ingredient in DARZALEX®, works in the body

What is DARZALEX FASPRO®? patient video

Introduces patients to DARZALEX FASPRO® and helps them feel more confident about treatment

Learn more about the science behind DARZALEX FASPRO® and DARZALEX®
Explore mechanism of action

Guiding your patients through their treatment with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)

APP/patient conversation tool

Supports APP-to-patient communication about the treatment journey, including how to help patients start and stay on treatment with DARZALEX® + Rd

Download tool
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) managing your multiple myeloma

Nurse conversation tool

Supports nurse-to-patient communication about multiple myeloma and treatment

Download tool
Doctor conversation starter guide thumbnail

DARZALEX FASPRO® doctor conversation starter guide

Assists patients with preparing questions for their doctor about DARZALEX FASPRO®

Download guide
Customized doctor conversation starter

Personalized doctor conversation starter

Allows patients to choose questions about DARZALEX FASPRO® and DARZALEX® to discuss with their doctor

Create guide
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) patient brochure thumbnailDARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) patient brochure thumbnail

Patient brochure

Educates patients on multiple myeloma and treatment with DARZALEX FASPRO®

Download brochure
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) patient dosing calendarDARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) patient dosing calendar

Dosing calendar

Helps patients stay on track with their DARZALEX FASPRO® treatment regimen

Download calendar
Janssen Compass® 1-844-628-1234Janssen Compass® 1-844-628-1234

J&J withMe

J&J withMe provides your patients with free, personalized support throughout their cancer treatment journey

Download brochure
Help start their treatment journey strong
Empower patients with these helpful videos, including a series to help them identify important questions to ask their care team as well as a walk-through of the patient treatment experience with DARZALEX FASPRO®.
View videos

DARZALEX® + Rd treatment duration brochure thumbnail

Treatment duration brochure

Outlines the proven benefits of long-term DARZALEX® + Rd treatment and provides APPs with ongoing support to help keep patients on treatment longer

Download brochure
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) patient dosing calendar

Dosing calendar

Helps patients stay on track with their DARZALEX FASPRO® treatment regimen

Download calendar
DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) patient and caregiver resources

Patient support organizations

Provide education, resources, and research for patients with multiple myeloma

See organizations
Janssen Compass® 1-844-628-1234

J&J withMe

J&J withMe provides your patients with free, personalized support throughout their cancer treatment journey

Download brochure
Learn more about the long-term safety and proven efficacy of continuous DARZALEX® + Rd
View the data

Dosing & Administration Guide for DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) thumbnail

Dosing and administration guide

Provides step-by-step instructions on how to administer DARZALEX FASPRO® and DARZALEX®

Download guide

Dosing and administration video

Demonstrates how to administer an injection of DARZALEX FASPRO®

Common questions and answers about treatment with DARZALEX FASPRO® and DARZALEX® for newly diagnosed, transplant-ineligible multiple myeloma

Explore FAQs

Get in touch

If you are a US healthcare professional, please provide your ZIP Code and contact information below if you would like us to get in touch with you.

The information you provide will be used by Janssen Biotech, Inc., our affiliates, and our service providers to contact you. Our Privacy Policy further governs the use of the information you provide.

*Required field.

Loading...

MOA=mechanism of action; Rd=lenalidomide (R) + dexamethasone (d).